Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma von Fishman, M.N, Srinivas, S, Hauke, R.J, Amato, R.J, Esteves, B, Cotreau, M.M, Strahs, A.L, Slichenmyer, W.J, Bhargava, P, Kabbinavar, F.F

Volltext

The Current Status of Camptothecin Analogues as Antitumor Agents von Slichenmyer, William J., Rowinsky, Eric K., Donehower, Ross C., Kaufmann, Scott H.

Volltext

Suramin Therapy for Patients With Symptomatic Hormone-Refractory Prostate Cancer: Results of a Randomized Phase III Trial Comparing Suramin Plus Hydrocortisone to Placebo Plus Hydr... von SMALL, E. J, MEYER, M, MARSHALL, M. E, REYNO, L. M, MEYERS, F. J, NATALE, R. B, LENEHAN, P. F, LIANG CHEN, SLICHENMYER, W. J, EISENBERGER, M

Volltext

Anticancer therapy targeting the erbB family of receptor tyrosine kinases von Slichenmyer, William J., Fry, David W.

Volltext

Serum Prostate-Specific Antigen Decline as a Marker of Clinical Outcome in Hormone-Refractory Prostate Cancer Patients: Association With Progression-Free Survival, Pain End Points,... von SMALL, Eric J, MCMILLAN, Alex, MEYER, Mark, LIANG CHEN, SLICHENMYER, William J, LENEHAN, Peter F, EISENBERGER, Mario

Volltext

Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage von SLICHENMYER, W. J, NELSON, W. G, SLEBOS, R. J, KASTAN, M. B

Volltext

PP 10 Biomarker discovery by pharmacological studies in a population based tumor model for VEGFR inhibitors von Lin, J, Feng, J, Bin, F, Xiaojian, S, Richard, N, Brooke, E, Slichenmyer, W, Chiu, M.I, Robinson, M.O

Volltext

Phase I and pharmacologic study of topotecan in patients with impaired renal function von O'REILLY, S, ROWINSKY, E. K, SLICHENMYER, W, DONEHOWER, R. C, FORASTIERE, A. A, ETTINGER, D. S, TIAN LING CHEN, SARTORIUS, S, GROCHOW, L. B

Volltext

Anticancer therapy targeting the erbB family of receptor tyrosine kinases von Slichenmyer, William J, Fry, David W

Volltext

CI-1033, a pan-erbB tyrosine kinase inhibitor von Slichenmyer, William J., Elliott, William L., Fry, David W.

Volltext

New Natural Products in Cancer Chemotherapy von Slichenmyer, William J., Von Hoff, Daniel D.

Volltext

Taxol: a new and effective anti-cancer drug von Slichenmyer, William J, Von Hoff, Daniel D

Volltext

Phase I and Pharmacologic Studies of Topotecan in Patients With Impaired Hepatic Function von O'Reilly, Seamus, Rowinsky, Eric, Slichenmyer, William, Donehower, Ross C., Forastiere, Arlene, Ettinger, David, Chen, Tian Ling, Sartorius, Susan, Bowling, Katherine, Smith, Jane, Brubaker, Abe, Lubejko, Barbara, Ignacio, Virna, Grochow, Louise B.

Volltext

Randomized Phase II Study of BR96-Doxorubicin Conjugate in Patients With Metastatic Breast Cancer von TOLCHER, A. W, SUGARMAN, S, GELMON, K. A, COHEN, R, SALEH, M, ISAACS, C, YOUNG, L, HEALEY, D, ONETTO, N, SLICHENMYER, W

Volltext

CI-1033, a pan-erbB tyrosine kinase inhibitor von Slichenmyer, William J, Elliott, William L, Fry, David W

Volltext

A Randomized Phase (PH) 2 Study with Exploratory Biomarker Analysis of Ficlatuzumab (F) A Humanized Hepatocyte Growth Factor (HGF) Inhibitory MAB in Combination with Gefitinib (G)... von Mok, T.S.K., Park, K., Geater, S.L., Agarwal, S., Han, M., Credi, M., McKee, K., Kuriyama, N., Slichenmyer, W., Tan, E.H.

Volltext

1198P - A Randomized Phase (PH) 2 Study with Exploratory Biomarker Analysis of Ficlatuzumab (F) A Humanized Hepatocyte Growth Factor (HGF) Inhibitory MAB in Combination with Gefiti... von Mok, T.S.K., Park, K., Geater, S.L., Agarwal, S., Han, M., Credi, M., McKee, K., Kuriyama, N., Slichenmyer, W., Tan, E.H.

Volltext

Final analysis of the phase II randomized discontinuation trial (RDT) of tivozanib (AV-951) versus placebo in patients with renal cell carcinoma (RCC) von Nosov, D., Bhargava, P., Esteves, W. B., Strahs, A. L., Lipatov, O. N., Lyulko, O. O., Anischenko, A. O., Chacko, R. T., Doval, D., Slichenmyer, W. J.

Volltext

Randomized phase II study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (p... von Mok, T., Tan, E., Park, K., Jac, J., Han, M., Payumo, F. C., Credi, M., McKee, K., Cotreau, M. M., Bhargava, P., Slichenmyer, W.

Volltext

A phase III, randomized, controlled study to compare tivozanib with sorafenib in patients (pts) with advanced renal cell carcinoma (RCC) von Motzer, R. J., Bhargava, P., Esteves, B., Al-Adhami, M., Slichenmyer, W., Nosov, D., Eisen, T., Sternberg, C. N., Hutson, T. E.

Volltext